DP11487 The Effects of Pharmaceutical Innovation on Cancer Mortality
|Author(s):||Pierre Dubois, Margaret K Kyle|
|Publication Date:||September 2016|
|Keyword(s):||cancer, health, innovation, pharmaceuticals|
|Programme Areas:||Industrial Organization|
|Link to this Page:||cepr.org/active/publications/discussion_papers/dp.php?dpno=11487|
Cancer is a leading cause of death in developed countries, and cancer treatments are the top category of pharmaceutical spending in the United States and Europe. This paper assesses whether novel cancer therapies are associated with a reduction in mortality. Using panel data from 11 developed countries, we study the relationship between mortality attributed to a specific cancer site and the availability of pharmaceutical treatments. The cross-country and cross-site variation over time allows us to isolate the decline in mortality attributable to new drugs from that due to changes in lifestyle and environmental factors. We correct for the endogeneity of mortality and the availability of new treatments using instrumental variables. On average, our results show a decline in mortality of 8-9% is associated with the availability of one new treatment for a cancer site. The gains vary across countries and cancer sites. Based on spending from 2000-2011, costs per statistical life saved ranged from $11-12K for bladder and liver cancers to over $150K for cervical, melanoma and stomach cancers. Across countries, Switzerland had the largest spending per statistical life at approximately $66K, while the UK had the lowest with $19K.